Skip to main content

A Case of Chronic Lyme Disease Successfully Managed Abroad: Lessons from Bosnia and Herzegovina

Published on:

Brief Presentation

M.B., a patient from Bosnia and Herzegovina, had been suffering from symptoms suggestive of Lyme disease, but her diagnosis was complicated by limited local knowledge and inadequate diagnostic testing. An initial ELISpot test performed abroad showed a weak Borrelia infection, highlighting several strains of Borrelia, including Borrelia afzelii, Borrelia garinii, and forms known as 'round bodies' that indicate persistent bacteria. However, local testing, likely using the standard ELISA method targeting the American strain Borrelia burgdorferi, returned a negative result. This outcome was likely influenced by the limitations of the test and M.B.’s immunosuppressed state.

Frustrated by the lack of recognition and support from local physicians, M.B. sought treatment in a neighboring country where she connected with a professor familiar with advanced Lyme disease treatment protocols. After undergoing a comprehensive six-month treatment, M.B. reports a near-complete recovery, marking a rare success in a region where chronic Lyme disease often goes unrecognized and untreated.

Conclusion

M.B.’s case illustrates the urgent need for greater awareness of chronic Lyme disease and the limitations of conventional diagnostic methods in Europe. Her successful recovery after long-term treatment abroad highlights the potential for significant health improvements when patients receive comprehensive care tailored to the complexity of Lyme disease. This case challenges the prevailing medical approach in many European countries, where Lyme disease is frequently underdiagnosed or misdiagnosed, and long-term treatment is often dismissed.

Medical History

  • Initial Symptoms and Diagnostic Challenges: M.B. exhibited symptoms consistent with Lyme disease, including fatigue, joint pain, and neurological issues. Despite seeking help from local physicians, her case was mismanaged due to inadequate diagnostic methods and a lack of familiarity with chronic Lyme disease among doctors in Bosnia and Herzegovina.
  • Diagnostic Testing Abroad: A test conducted using the ELISpot method, which measures cellular immune responses to several Borrelia species, confirmed a weak infection. The test identified Borrelia afzelii and Borrelia garinii, strains common in Europe but less recognized in many local healthcare settings, as well as persistent 'round bodies' of the bacteria, indicative of chronic infection.
  • Local Diagnostic Failure: M.B. also underwent testing at a local laboratory, presumed to be ELISA, which returned a negative result. The test likely targeted the American strain of Borrelia (Borrelia burgdorferi), which is not prevalent in Europe, making the result inaccurate. Her long-term immune suppression may have further skewed the results, contributing to the diagnostic challenges.

Symptoms

  • Fatigue: M.B. experienced significant, persistent fatigue, a hallmark symptom of Lyme disease.
  • Musculoskeletal Pain: She reported chronic joint pain and muscle aches, which affected her mobility and quality of life.
  • Neurological Symptoms: In addition to physical symptoms, M.B. exhibited neurological issues, including cognitive difficulties and brain fog, commonly seen in late-stage Lyme disease.
  • Generalized Weakness: The patient’s overall strength and vitality were significantly reduced, leading to a diminished ability to perform daily tasks.

Diagnostic Tests

  1. ELISpot Test (conducted abroad): The test returned a weak positive result, identifying several strains of Borrelia—Borrelia afzelii and Borrelia garinii—and indicating chronic bacterial forms known as 'round bodies.' This test is more sensitive and specific for detecting active Borrelia infection than standard antibody tests, particularly in immunosuppressed patients.
  2. Local Test (presumed ELISA): A negative result was obtained from a local laboratory, which likely used an ELISA test designed to detect the American strain, Borrelia burgdorferi. Given the patient’s suppressed immune system and the test's focus on the wrong Borrelia strain, the negative result was misleading.

Outcomes

  • Abandonment by Local Healthcare Providers: M.B. was left without a diagnosis or appropriate treatment after her negative local test, and local doctors, unfamiliar with the nuances of chronic Lyme disease, dismissed her symptoms and the weak positive result from the ELISpot test.
  • Long-Term Treatment Abroad: After seeking help outside of Bosnia and Herzegovina, M.B. was fortunate to connect with a professor in a neighboring country who recognized the complexity of her infection. Over six months, M.B. underwent long-term therapy that addressed the multiple forms of Borrelia present in her body, including the persistent 'round body' forms of the bacteria.
  • Near-Complete Recovery: Following treatment, M.B. reports a remarkable recovery. Her health has improved significantly, and she now considers herself nearly back to her normal condition, a rare outcome for patients in the region.

Differential Diagnosis

  • Chronic Lyme Disease: Given the positive ELISpot test and M.B.’s clinical symptoms, chronic Lyme disease is the most probable diagnosis. The identification of Borrelia afzelii and Borrelia garinii further supports this diagnosis, as these strains are common in Europe.
  • Other Chronic Infections or Coinfections: The patient’s persistent symptoms could also suggest possible coinfections with other tick-borne pathogens. While no other infections were confirmed in her case, the possibility remains given the multisystem nature of Lyme disease.
  • Fibromyalgia or Chronic Fatigue Syndrome (CFS): M.B.’s fatigue and pain could potentially be misdiagnosed as fibromyalgia or CFS in the absence of proper Lyme disease testing. These conditions often share overlapping symptoms with chronic Lyme disease.

Future Recommendations

  • Wider Adoption of Advanced Diagnostic Tools: M.B.’s case highlights the need for broader recognition and use of advanced diagnostic methods, such as ELISpot and Western Blot, in Bosnia and Herzegovina and throughout Europe. These tools are more effective at detecting European strains of Borrelia and are crucial for diagnosing chronic Lyme disease.
  • Long-Term Treatment Protocols: M.B.’s success with long-term treatment underscores the importance of extended antibiotic regimens and adjunctive therapies for chronic Lyme disease, particularly in patients with complex infections or persistent forms of Borrelia. The success of her therapy suggests that the standard short-term courses of antibiotics often prescribed for Lyme disease may be insufficient for chronic or late-stage cases.
  • Education and Awareness for Healthcare Providers: Increased awareness and training are needed for infectious disease specialists and general practitioners in Europe, where chronic Lyme disease is often underdiagnosed. Improved education could lead to earlier detection, preventing the progression to debilitating chronic illness.
  • Advocacy for Chronic Lyme Disease Recognition: M.B.’s case reflects a broader issue across Europe, where chronic Lyme disease remains unrecognized by many healthcare authorities. Advocacy efforts should focus on updating diagnostic and treatment guidelines to reflect the reality of chronic Lyme and its long-term impact on patients.

Discussion

Lyme disease, caused by various species of the Borrelia bacterium, is the most common tick-borne illness in Europe and North America. In recent years, there has been increasing recognition of chronic Lyme disease, a condition characterized by persistent symptoms long after the initial infection. However, chronic Lyme disease remains controversial in many countries, including Bosnia and Herzegovina, where the medical community often relies on outdated or insufficient diagnostic methods, such as the ELISA test, which primarily targets the American strain Borrelia burgdorferi.

M.B.’s case illustrates the diagnostic challenges faced by patients in regions where Lyme disease awareness is limited. The ELISpot test, used abroad, identified weak but clinically significant infection with European strains of Borrelia, including Borrelia afzelii and Borrelia garinii. These strains are common in Europe, yet local healthcare providers, unfamiliar with these species, were unable to properly diagnose or treat her infection.

The issue of immune suppression is another complicating factor in M.B.’s case. Many patients with chronic Lyme disease exhibit weakened immune responses, which can result in false-negative test results when using traditional serological methods. This further delays diagnosis and treatment, as seen in M.B.’s experience.

The comprehensive treatment that M.B. received abroad demonstrates the potential for recovery in chronic Lyme disease when patients receive appropriate care. Her near-complete recovery following long-term antibiotic therapy and adjunctive treatments challenges the conventional wisdom in many European countries, where Lyme disease is often thought to be easily treatable with short courses of antibiotics.

Broader Implications

M.B.’s case highlights the broader issue of undiagnosed or misdiagnosed Lyme disease in Europe, where chronic Lyme disease is still not widely accepted. This lack of recognition leaves millions of patients suffering without proper care. The discrepancy between testing methods and treatment protocols across Europe underscores the need for an updated, evidence-based approach to Lyme disease diagnosis and management.

Her case is a rare success story, showing that long-term treatment can result in significant improvements in health and quality of life. It serves as a call to action for greater investment in Lyme disease research, education for healthcare providers, and updated diagnostic and treatment guidelines that reflect the complexities of the disease. M.B.’s journey from a misdiagnosed patient in Bosnia to a near-recovered individual treated abroad is a testament to the importance of recognizing and addressing chronic Lyme disease on a global scale.

Analysis of the Case of Chronic Lyme Disease: Implications for Diagnosis and Treatment in Europe

The case of M.B., a woman from Bosnia and Herzegovina who suffered from chronic Lyme disease and eventually found treatment abroad, raises important considerations regarding the state of Lyme disease diagnosis and management in Europe. As a professional in the field of infectious diseases, this case highlights several clinical, diagnostic, and systemic failings that are reflective of broader issues within the healthcare landscape, particularly in regions with limited access to specialized care for tick-borne illnesses.

Diagnostic Challenges: Beyond the ELISA Test

The key diagnostic issue presented in M.B.’s case is the reliance on the ELISA test, a method that has well-documented limitations in detecting Lyme disease, particularly in its chronic stages or in immunocompromised patients. The ELISA test, which is widely used across Europe, is predominantly designed to detect antibodies against Borrelia burgdorferi, the strain most commonly associated with Lyme disease in North America. However, Europe is home to a broader spectrum of Borrelia species, including Borrelia afzelii and Borrelia garinii, both of which were identified in M.B.’s case by more advanced diagnostic methods.

One of the fundamental problems with relying on serological tests such as ELISA in diagnosing Lyme disease is that they are indirect—they measure the body's immune response to the infection, not the infection itself. This becomes problematic in patients with immune suppression, such as M.B., where antibody production may be muted or absent, leading to false-negative results. This limitation makes it imperative to move beyond conventional antibody-based tests and to adopt more sensitive and specific diagnostic tools, such as the ELISpot test used in M.B.’s case. ELISpot measures T-cell responses, allowing for detection of active infection even when the immune system fails to produce detectable antibodies.

From a professional perspective, this case highlights the need for a paradigm shift in Lyme disease diagnostics. Laboratories and clinicians in endemic regions of Europe should prioritize advanced diagnostic techniques, including ELISpot and PCR-based tests, over traditional ELISA and even Western Blot, which also suffer from the same immunological shortcomings. Additionally, these tests must be standardized across Europe, as the current diagnostic inconsistency leads to widespread misdiagnosis and underdiagnosis.

The Complexity of Chronic Lyme Disease: Moving Beyond Acute Models

Chronic Lyme disease, as exhibited in M.B.’s case, is an area of ongoing controversy within the medical community, largely due to the failure to reconcile acute models of infection with the complexities of long-term, persistent infections. The conventional wisdom in many European countries still treats Lyme disease as an acute infection, where a short course of antibiotics is considered curative. This model works well for early Lyme disease, particularly when diagnosed and treated in its early stages. However, it fails to address the reality of patients like M.B. who, due to diagnostic delays or mismanagement, present with chronic, multisystemic symptoms that persist beyond standard treatments.

In the case of M.B., the presence of persistent Borrelia forms, including ‘round bodies’ (also referred to as cystic forms), suggests that chronic Lyme disease may involve bacterial persistence mechanisms that are not fully addressed by short-term antibiotic therapy. These forms of Borrelia are known to evade the immune system and antibiotics, potentially leading to relapses after what appears to be successful treatment. This necessitates a more nuanced understanding of Lyme disease pathophysiology and a recognition that long-term antibiotic and adjunctive therapies may be necessary for some patients. The reluctance of the medical community to accept chronic Lyme as a legitimate condition needing long-term treatment protocols may stem from a lack of robust clinical trials, but patient cases like M.B.’s suggest that there is a real and significant subset of patients who benefit from such an approach.

The issue of treatment duration and complexity in chronic Lyme disease is not dissimilar to other persistent bacterial infections like tuberculosis, where long-term antibiotic regimens are the standard of care. In this context, chronic Lyme disease should be treated with a similar mindset: individualized, long-term, and multifaceted treatment protocols aimed at addressing both the bacterial infection and its systemic consequences.

The Impact of Healthcare Infrastructure and Physician Awareness

M.B.’s case also speaks to broader healthcare infrastructure issues, particularly in less affluent or medically underserved regions such as Bosnia and Herzegovina. The local physicians’ inability to properly diagnose and treat her Lyme disease underscores a significant gap in both medical education and the healthcare system’s capacity to address complex, multi-systemic infections. Many countries in Eastern Europe have healthcare systems that are overburdened and underfunded, making it difficult for physicians to stay current with advances in diagnostic techniques and treatment protocols. Moreover, the influence of outdated guidelines, which often downplay the existence or severity of chronic Lyme disease, creates a clinical environment in which patients like M.B. are frequently misdiagnosed or dismissed.

This case illustrates the critical need for continuing medical education (CME) programs specifically targeted at infectious disease specialists and general practitioners in Europe. A significant proportion of healthcare providers are unaware of the broad spectrum of Borrelia species present in Europe or the limitations of conventional diagnostic tools. CME programs could equip physicians with up-to-date knowledge on the latest diagnostic technologies (e.g., ELISpot, PCR) and emerging research on chronic Lyme disease treatment strategies, such as combination antibiotic therapies and the use of immunomodulatory agents.

Lessons for Global Health Policy and Lyme Disease Advocacy

Beyond the clinical and diagnostic dimensions, M.B.’s case serves as a call to action for global health policy reform regarding Lyme disease. The divergence in testing and treatment protocols between countries reflects an underlying inequity in healthcare access, which is particularly stark in cases of complex diseases like Lyme. Patients in lower-income countries or regions with limited access to advanced medical care are left without options and are often forced to seek treatment abroad, as M.B. did. This creates a healthcare system that disproportionately disadvantages the most vulnerable patients, exacerbating health disparities across Europe.

One of the most effective ways to address this gap is through advocacy at the national and European Union levels to establish Lyme disease as a priority public health issue. This would involve harmonizing diagnostic and treatment guidelines across the EU, ensuring that all member states have access to the same standard of care. Such efforts would not only help patients like M.B., but also reduce the overall economic burden of untreated or improperly treated Lyme disease, which results in significant long-term healthcare costs due to chronic illness and disability.

Conclusion: A Holistic Approach to Lyme Disease Management

In conclusion, M.B.’s case exemplifies many of the key challenges and lessons surrounding Lyme disease diagnosis and treatment in Europe. The failures of the local healthcare system, from inadequate diagnostic tools to the dismissal of chronic Lyme disease, are indicative of a broader crisis in Lyme disease management. Her successful recovery after long-term treatment abroad serves as a stark reminder of the potential for significant patient outcomes when a comprehensive and tailored approach to Lyme disease is implemented.

To improve Lyme disease care, European healthcare systems must embrace more advanced diagnostic methods, recognize the reality of chronic Lyme disease, and support long-term, individualized treatment protocols for those suffering from persistent infections. Furthermore, greater investment in medical education and advocacy for Lyme disease recognition is essential to closing the gap between current practice and optimal care, ensuring that patients like M.B. no longer have to travel abroad to receive the treatment they need and deserve. This case is not only a testament to M.B.'s resilience, but a call to action for healthcare reform across Europe.


Latest Case Studies

Latest publications